Site professionnel spécialisé en Rhumatologie
OP0138. Sánchez-Alonso F, Bohórquez C, Diaz-Torne C et al. Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy:…
OP0016. Deodhar A, Van den Bosch F, Poddubnyy D et al. Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled phase 3 trial.…
OP0255. Merola JF, McInnes I, Ritchlin CT et al. Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy & safety from…
OP0221. Ruperto N, Chertok E, Dehoorne J et al. Efficacy of secukinumab in enthesitis-related arthritis: results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA). Eular 2022. Figure…
OP0263. Hartman L, Opris-Belinski D, Bos R et al. Favorable balance of benefit and harm of long-term, low-dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: the…
OP0153. Hamroun S, Couderc M, Flipo RM et al. Preconceptional nsaid treatment is associated with longer time-to-conception in women with spondyloarthritis: analysis of the prospective GR2 cohort. Eular 2022. OP0126.…
OP0270. Boers M, Hartman L, Opris-Belinski D et al. Tapering of long-term, low-dose glucocorticoids in senior rheumatoid arthritis patients: follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial. Eular 2022.
OP0023. Deodhar A, Kivitz A, Magrey M et al. A randomized, double-blind trial comparing secukinumab 300 mg and 150 mg at week 52 in patients with ankylosing spondylitis who did…
OP0261. Michielsens C, den Broeder N, van den Hoogen F et al. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomized controlled…
OP0070. Krijbolder D, Verstappen M, van Dijk B et al. Intervention with methotrexate in arthralgia at risk for rheumatoid arthritis to reduce the development of persistent arthritis and its disease…
Abstract OP0020. Hellamand P, Van de Sande MGH, Midtbøll Ørnbjerg L et al. Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries…
OP0269. Szekanecz C, Charles-Schoeman C, Vranix I et al. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. Eular 2022.
LB006. Dasgupta B, Unizony S, Warrington KJ et al. Sarilumab in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR). Eular 2022. Figure…
OP0260. D’Agostino MA, Boers M, Gaillez C et al. Responsiveness of a combined power Doppler and Greyscale ultrasound score for assessing synovitis at joint level in psoriatic arthritis patients with…
